about
Immunotherapy for lung cancerThe "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Chemotherapy enhances cross-presentation of nuclear tumor antigensStrong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Transient Treg depletion enhances therapeutic anti-cancer vaccination.Interferon-gamma response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis.Combination immune checkpoint blockade as an effective therapy for mesotheliomaBibliometric analysis of gaps in research on asbestos-related diseases: declining emphasis on public health over 26 yearsQuantitation of defective and ecotropic viruses during LP-BM5 infection by real time PCR and RT-PCRNeo-antigen specific T cell responses indicate the presence of metastases before imaging
P50
Q26751254-3C4C810A-1D1A-47F5-9872-65BD3F5D4E86Q33736218-DCE62DDF-EC7C-4C2E-B285-C79F5586F659Q34145877-B8E58268-803E-4F08-8DFF-B1FE5DD23B46Q34226903-507B8857-6129-4F59-957F-A801DBE9B4AEQ35799065-6192DD00-1BEA-43C5-8641-1D3B5FC8BBC2Q37660771-DEEEB3BC-FCAC-4076-9695-43CC1E39783DQ42981339-ADAEC68F-5A03-46AF-9843-4766614192A8Q57138329-D1CDCAEC-4C06-432B-A496-696B4D26FDFCQ60213521-EF6DCFCD-4D87-4C92-9084-A87E5FD06AD4Q81304628-A18C9CB0-5602-490B-A29A-78AF1155891BQ90641351-8FB95D6A-2331-4F05-9A2E-EB0E12AC8047
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1551-5579
@en
name
Scott A Fisher
@ast
Scott A Fisher
@en
Scott A Fisher
@es
Scott A Fisher
@nl
type
label
Scott A Fisher
@ast
Scott A Fisher
@en
Scott A Fisher
@es
Scott A Fisher
@nl
prefLabel
Scott A Fisher
@ast
Scott A Fisher
@en
Scott A Fisher
@es
Scott A Fisher
@nl
P106
P1153
57203278674
P31
P496
0000-0003-1551-5579